(Q42977367)

English

Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.

scientific article published on 24 March 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

pegylated interferon

1 reference

based on heuristic

inferred from title

2

object named as

M Sulkowski

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

author name string

J McHutchison

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

24 March 2008

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Journal of Viral Hepatitis

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

475-481

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2008.00973.X

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2008.00973.X

21 January 2018

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2008.00973.X

21 January 2018

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2008.00973.X

21 January 2018

Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2008.00973.X

21 January 2018

Identifiers

10.1111/J.1365-2893.2008.00973.X

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42977367&oldid=1590425856"